Wedbush restated their outperform rating on shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) in a research report sent to investors on Thursday morning. The firm currently has a $17.00 target price on the stock.

Several other analysts have also recently issued reports on the company. Cowen and Company reaffirmed a buy rating on shares of Catabasis Pharmaceuticls in a report on Wednesday, June 8th. Zacks Investment Research raised Catabasis Pharmaceuticls from a hold rating to a buy rating and set a $4.25 price objective on the stock in a report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $19.05.

Catabasis Pharmaceuticls (NASDAQ:CATB) traded down 2.08% during mid-day trading on Thursday, hitting $6.12. 1,312,402 shares of the stock traded hands. Catabasis Pharmaceuticls has a 52-week low of $3.31 and a 52-week high of $10.83. The firm’s 50-day moving average is $4.69 and its 200 day moving average is $4.78. The firm’s market cap is $94.13 million.

Catabasis Pharmaceuticls (NASDAQ:CATB) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.04. Equities analysts predict that Catabasis Pharmaceuticls will post ($2.47) EPS for the current fiscal year.

An institutional investor recently bought a new position in Catabasis Pharmaceuticls stock. Bridgeway Capital Management Inc. purchased a new position in shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 27,700 shares of the company’s stock, valued at approximately $102,000. Bridgeway Capital Management Inc. owned about 0.18% of Catabasis Pharmaceuticls at the end of the most recent quarter. Hedge funds and other institutional investors own 66.58% of the company’s stock.

About Catabasis Pharmaceuticls

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Stock Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related stocks with our FREE daily email newsletter.